Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate that is approved for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL). After binding CD22 on ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

Infantile ALL occurs in children under age one. It’s a rare and aggressive leukemia that typically has a poor outlook. Treatment involves chemo and sometimes a stem cell transplant. Leukemia refers to ...

Precursor B-cell acute lymphoblastic leukemia is a fast-growing leukemia that affects early B cells in bone marrow. It’s both more common and has a better outlook in children. Leukemia is a type of ...

Among the efficacy evaluable patients, 42% achieved complete remission within 3 months. The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the ...

B-Cell Acute Lymphoblastic Leukemia for Adults: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a rare but aggressive form of ...

Three clinically available drugs could pave the way for safer and more effective treatments for one of the most aggressive ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

Credit: Getty Images ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.